摘要
目的观察二甲双胍对T2DM早期糖尿病肾病(DN)的疗效。方法将118例T2DM并发早期DN的患者随机分为二甲双胍组和阿卡波糖组。两组分别在服用二甲双胍及阿卡波糖的基础上口服贝那普利片20mg/d,疗程24周。观察两组治疗前后的血压、血糖、HbA1c、稳态、模型胰岛素-抵抗指数(HOMA-IR)、高敏C反应蛋白(hsC-RP)、UAER的变化。结果二甲双胍组治疗前后的血压、血糖、HbA1c、HOMA-IR、hsC-RP、UAER的变化明显,差异有统计学意义。UAER治疗前(106.1±20.45)μg/min,治疗后(52.12±10.34)μg/min,(P<0.05);阿卡波糖组血压、hsC-RP、UAER治疗前后变化差异无统计学意义(P>0.05)。结论对于T2DM早期DN的患者,二甲双胍在降糖的同时,也能降低UAER。
Objective To observe the therapeutic effects of metfonnin on early diabetic nephropathy in T2DM patients. Methods The 118 T2DM patients with early diabetic nephropathy were randomized into two groups： metformin group and acarbose group. Both groups were administered benazepril 20 mg/d at the same time in addition to metformin and acarbose respectively. The course of treatment was of 24 weeks. The changes in parameters including blood pressure （BP）, plasma glucose （PC;）, HbAlc, HOMA-IR, high sensitivity C- reaction protein （hsC-RP）, and urinary albumin excretory rate （UAER） were observed after treatment. Resdts In the metformin group, the post-treatment changes in BP, PC,, HbA1 c, HOMA-IR, hsC-RP, and UAER showed significant difference （all P〈0. 05）, and the UAER changed from 106. 1±20. 45 rig/rain to 52. 12±10. 34 μg/rnin （P〈0. 05）. In the acarbose group, there were no significant changes in BP, HOMA-IR, hsC- RP, UAER after treatment （P〉0. 05）. Condusion For the T2DM patients with early diabetic nephropathy, metformin can lower plasma glucose and reduce UAER.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2012年第7期543-545,共3页
Chinese Journal of Diabetes
关键词
二甲双胍
糖尿病
2型
糖尿病肾病
尿白蛋白排泄率
Metformin
Diabetes mellitus, type 2
Diabetic nephropathy
Urinary albuminexcretory rate
